Nilotinib Zentiva: Uses, Dosage & Side Effects
A second-generation BCR-ABL tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
Nilotinib Zentiva is a prescription oral capsule containing nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Nilotinib works by selectively blocking the BCR-ABL oncoprotein, the abnormal fusion protein responsible for driving uncontrolled white blood cell proliferation in CML. By inhibiting this protein, nilotinib halts the growth of leukemic cells and allows normal blood cell production to resume. This medication is used both as first-line therapy in newly diagnosed adult patients with chronic-phase CML and as second-line therapy in patients who are resistant to or intolerant of prior treatment, including imatinib. Nilotinib must be taken on an empty stomach due to food-related increases in drug absorption that can cause dangerous cardiac side effects.
Quick Facts: Nilotinib Zentiva
Key Takeaways
- Nilotinib Zentiva is a generic second-generation BCR-ABL tyrosine kinase inhibitor indicated for treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in both newly diagnosed and treatment-resistant patients.
- The capsules must be taken strictly on an empty stomach — no food for 2 hours before and 1 hour after dosing — because food dramatically increases absorption and raises the risk of dangerous QT prolongation.
- Regular ECG monitoring is mandatory before and during treatment, as nilotinib can prolong the QT interval and has been associated with sudden cardiac death in rare cases.
- Treatment-free remission (TFR) may be achievable for eligible patients who maintain a deep, sustained molecular response (MR4.5) for at least 2 years under specialist supervision.
- Common side effects include rash, headache, nausea, and fatigue, while serious adverse effects requiring close monitoring include myelosuppression, hepatotoxicity, pancreatitis, and cardiovascular events.
What Is Nilotinib Zentiva and What Is It Used For?
Nilotinib Zentiva contains the active substance nilotinib, which belongs to a class of medications known as tyrosine kinase inhibitors (TKIs). These are targeted cancer therapies designed to interfere with specific molecular pathways that drive the growth and survival of cancer cells. Nilotinib is classified as a second-generation BCR-ABL TKI, meaning it was developed to be more potent and selective than imatinib, the first-generation TKI that revolutionized CML treatment when it was introduced in the early 2000s.
Chronic myeloid leukemia is a cancer of the white blood cells that originates in the bone marrow. In approximately 95% of CML cases, the disease is driven by a specific genetic abnormality known as the Philadelphia chromosome. This abnormality results from a reciprocal translocation between chromosomes 9 and 22 — designated t(9;22)(q34;q11) — which creates a novel fusion gene called BCR-ABL1. The BCR-ABL1 gene produces an abnormal protein (BCR-ABL) with constitutively active tyrosine kinase activity. This means the BCR-ABL protein is permanently switched on, continuously sending growth signals that drive the uncontrolled proliferation of myeloid (white blood) cells in the bone marrow and blood.
Nilotinib works by binding to the ATP-binding site of the BCR-ABL kinase domain with high affinity and selectivity. By occupying this critical binding site, nilotinib prevents the BCR-ABL protein from phosphorylating its downstream substrates — the signaling molecules that transmit growth and survival signals to the leukemic cell. Without these signals, the CML cells can no longer proliferate and undergo programmed cell death (apoptosis). Compared with imatinib, nilotinib binds approximately 20–50 times more potently to the ABL kinase domain in its inactive conformation. This enhanced potency translates into deeper and faster molecular responses in clinical practice.
In addition to inhibiting BCR-ABL, nilotinib also inhibits the kinase activity of several related proteins, including platelet-derived growth factor receptor (PDGFR), the stem cell factor receptor c-KIT, colony-stimulating factor receptor 1 (CSF-1R), and discoidin domain receptors (DDR1 and DDR2). This broader kinase inhibition profile contributes to nilotinib's therapeutic effects but also underlies some of its side effects, particularly cardiovascular and metabolic adverse events.
Nilotinib Zentiva is indicated for the following clinical settings:
- Newly diagnosed adult patients with chronic-phase Ph+ CML: As first-line therapy, nilotinib has demonstrated superiority over imatinib in achieving early and deep molecular responses. The ENESTnd (Evaluating Nilotinib Efficacy and Safety in clinical Trials – newly diagnosed patients) trial, a landmark phase III study enrolling 846 patients, showed that nilotinib 300 mg twice daily achieved a significantly higher rate of major molecular response (MMR) at 12 months compared with imatinib 400 mg once daily (44% versus 22%). The rate of complete cytogenetic response was also significantly higher with nilotinib.
- Adult patients with chronic-phase or accelerated-phase Ph+ CML resistant to or intolerant of prior therapy including imatinib: In the pivotal phase II registration study, nilotinib 400 mg twice daily demonstrated substantial efficacy in imatinib-resistant or intolerant patients, with major cytogenetic response rates of approximately 59% in chronic-phase patients and 32% in accelerated-phase patients. Nilotinib is active against most BCR-ABL kinase domain mutations that confer resistance to imatinib, with the notable exception of the T315I mutation.
Long-term follow-up data from the ENESTnd trial have confirmed that nilotinib provides sustained benefits over imatinib, with significantly fewer patients progressing to accelerated phase or blast crisis. At 10-year follow-up, progression-free survival and overall survival rates remain excellent with nilotinib, and more patients on nilotinib have achieved the deep molecular responses required to attempt treatment-free remission (TFR). TFR represents one of the most significant advances in CML management: patients who achieve and sustain a deep molecular response (MR4.5 or better, corresponding to BCR-ABL1 transcripts ≤0.0032% on the International Scale) for at least 2 years may be eligible to discontinue TKI therapy under close molecular monitoring.
Nilotinib Zentiva is a generic version of nilotinib, which was originally developed and marketed by Novartis under the brand name Tasigna. Generic medications must meet rigorous bioequivalence standards established by regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), ensuring that they deliver the same therapeutic effect as the original branded product. The availability of generic nilotinib helps improve patient access to this critical cancer therapy.
What Should You Know Before Taking Nilotinib Zentiva?
Contraindications
Nilotinib is contraindicated — meaning it must not be used — in several specific clinical situations. The most critical contraindication relates to cardiac safety. Patients with a known history of long QT syndrome, clinically significant heart disease (including recent myocardial infarction, unstable angina, or congestive heart failure), or uncorrected electrolyte abnormalities (particularly hypokalemia or hypomagnesemia) must not receive nilotinib. The drug is also contraindicated in patients with known hypersensitivity to nilotinib or any of its excipients.
Patients with severe hepatic impairment (Child-Pugh Class C) should not take nilotinib, as the drug is extensively metabolized by the liver and impaired hepatic function can lead to significantly elevated drug levels with increased toxicity risk. Additionally, nilotinib must not be used concomitantly with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, ritonavir, or grapefruit juice) or with medications known to significantly prolong the QT interval, as these combinations create an unacceptable risk of life-threatening cardiac arrhythmias.
Warnings and Precautions
Nilotinib carries several important warnings that necessitate careful monitoring throughout the treatment period. The most significant safety concern is QT prolongation. Nilotinib can prolong the QTc interval in a concentration-dependent manner. QT prolongation increases the risk of potentially fatal ventricular arrhythmias, including torsades de pointes and sudden cardiac death. Cases of sudden death have been reported in clinical trials and post-marketing surveillance. For this reason, an ECG must be obtained at baseline, at 7 days after initiation of therapy, periodically thereafter (as clinically indicated), and after any dose adjustment. Electrolytes (potassium, magnesium, and calcium) must be checked and corrected before starting therapy and monitored periodically during treatment.
Myelosuppression is another important adverse effect. Nilotinib can cause severe neutropenia, thrombocytopenia, and anemia. Complete blood counts must be performed every 2 weeks for the first 2 months of therapy and monthly thereafter, or as clinically indicated. Dose modifications or temporary treatment interruptions may be necessary if severe cytopenias develop.
Hepatotoxicity has been reported with nilotinib, including elevations in bilirubin, transaminases (ALT, AST), and alkaline phosphatase. Liver function tests should be monitored monthly or as clinically indicated, and treatment should be interrupted if significant elevations occur. Rare cases of hepatic failure requiring liver transplantation have been reported.
Pancreatitis is a known complication of nilotinib therapy. Serum lipase levels should be monitored periodically. If lipase elevations are accompanied by abdominal symptoms suggestive of pancreatitis, nilotinib should be withheld and appropriate diagnostic evaluation should be performed.
Cardiovascular events represent an important long-term safety concern with nilotinib. Peripheral arterial occlusive disease (PAOD), ischemic heart disease, and ischemic cerebrovascular events have been reported at a higher rate in patients treated with nilotinib compared with imatinib. Before starting therapy, patients should be assessed for cardiovascular risk factors, and cardiovascular status should be monitored regularly throughout treatment. Patients with a history of or risk factors for cardiovascular disease may require more intensive monitoring.
Tumor lysis syndrome (TLS) has been reported rarely in patients with CML treated with nilotinib. Patients at risk for TLS (those with high tumor burden) should receive adequate hydration and correction of uric acid levels before initiating treatment.
Nilotinib must be taken on an empty stomach. No food should be consumed for at least 2 hours before and at least 1 hour after taking the dose. Food significantly increases the bioavailability of nilotinib by up to 82%, which substantially increases the risk of QT prolongation and other dose-dependent toxicities. Only water is permitted during these fasting periods. This requirement applies to every single dose and is critical for patient safety.
Pregnancy and Breastfeeding
Nilotinib can cause fetal harm and is classified in pregnancy risk categories that advise against use during pregnancy. Animal studies have demonstrated embryotoxicity and teratogenicity at doses resulting in exposures similar to or lower than the therapeutic human exposure. Women of childbearing potential must use highly effective contraception during treatment and for at least 2 weeks after the last dose. If a patient becomes pregnant while taking nilotinib, she should be informed of the potential hazard to the fetus, and the risks and benefits of continuing therapy must be carefully evaluated by the treating specialist.
It is not known whether nilotinib or its metabolites are excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during treatment and for at least 2 weeks after the final dose. Men taking nilotinib should also be aware that the drug may affect fertility, although the clinical significance of this effect is not fully characterized.
How Does Nilotinib Zentiva Interact with Other Drugs?
Drug interactions with nilotinib are clinically significant and can result in either increased toxicity or reduced efficacy. Understanding these interactions is essential for safe prescribing. Nilotinib is primarily metabolized by cytochrome P450 3A4 (CYP3A4) in the liver, and it also functions as an inhibitor of several CYP enzymes and the P-glycoprotein (P-gp) drug transporter. This dual role as both a substrate and an inhibitor of metabolic pathways creates a complex interaction profile.
Major Interactions
Certain drug combinations with nilotinib are considered dangerous and should be avoided entirely or managed with extreme caution. Strong CYP3A4 inhibitors dramatically increase nilotinib plasma concentrations, magnifying the risk of QT prolongation, hepatotoxicity, and myelosuppression. Similarly, co-administration with other drugs that prolong the QT interval creates an additive or synergistic risk of life-threatening cardiac arrhythmias.
Conversely, strong CYP3A4 inducers significantly reduce nilotinib blood levels, potentially rendering the treatment ineffective against the leukemia. This could lead to disease progression or loss of molecular response, which are serious outcomes in CML management.
| Interacting Drug/Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Ketoconazole, Itraconazole, Voriconazole | Strong CYP3A4 inhibition | Increased nilotinib exposure up to 3-fold; risk of QT prolongation and toxicity | Contraindicated. Use alternative antifungal agents. |
| Clarithromycin, Telithromycin | Strong CYP3A4 inhibition | Significantly elevated nilotinib levels | Contraindicated. Use azithromycin as alternative. |
| Ritonavir, other HIV protease inhibitors | Strong CYP3A4 inhibition | Markedly increased nilotinib levels; enhanced cardiac and hepatic toxicity | Contraindicated. Consult HIV specialist for alternatives. |
| Rifampicin, Rifabutin | Strong CYP3A4 induction | Reduced nilotinib exposure by up to 80%; risk of treatment failure | Contraindicated. Use alternative anti-tuberculosis regimens. |
| Phenytoin, Carbamazepine, Phenobarbital | Strong CYP3A4 induction | Significantly reduced nilotinib levels; treatment failure risk | Avoid. Consider non-enzyme-inducing antiepileptics (e.g., levetiracetam). |
| Amiodarone, Sotalol, Haloperidol | QT prolongation (additive effect) | Increased risk of torsades de pointes and sudden cardiac death | Avoid. If unavoidable, intensive ECG monitoring is mandatory. |
| Grapefruit juice, Seville oranges | Intestinal CYP3A4 inhibition | Increased nilotinib absorption and plasma levels | Must be avoided completely during treatment. |
Minor Interactions
Some drug interactions with nilotinib are less severe but still warrant clinical awareness and possible dose adjustments. Because nilotinib itself inhibits CYP3A4, CYP2C8, CYP2C9, CYP2D6, and P-glycoprotein, it can increase the plasma concentrations of drugs that are substrates for these enzymes and transporters. This means that patients taking nilotinib may experience enhanced effects or toxicities from their concomitant medications.
| Interacting Drug/Class | Mechanism | Recommendation |
|---|---|---|
| Warfarin | Nilotinib inhibits CYP2C9, increasing warfarin exposure | Monitor INR closely; consider dose reduction of warfarin. |
| Midazolam (CYP3A4 substrate) | Nilotinib inhibits CYP3A4, increasing midazolam levels | Reduce midazolam dose; monitor for excessive sedation. |
| Metoprolol, Codeine (CYP2D6 substrates) | Nilotinib inhibits CYP2D6 | Monitor for enhanced effects; dose adjustments may be needed. |
| Proton pump inhibitors (PPIs) | Increased gastric pH reduces nilotinib solubility and absorption | Separate administration. PPIs should be avoided if possible; H2 blockers preferred. |
| Digoxin (P-gp substrate) | Nilotinib inhibits P-glycoprotein transport | Monitor digoxin levels; reduce dose if needed. |
Patients should inform their healthcare provider about all herbal supplements and dietary products they consume. St. John's wort (Hypericum perforatum) is a potent CYP3A4 inducer and must be avoided, as it can dramatically reduce nilotinib levels. Grapefruit, Seville oranges, and star fruit contain compounds that inhibit intestinal CYP3A4 and must be excluded from the diet during nilotinib treatment. Patients should also be cautious about over-the-counter supplements that may affect liver enzymes or electrolyte balance.
What Is the Correct Dosage of Nilotinib Zentiva?
The dosage of nilotinib is carefully calibrated based on the clinical indication (newly diagnosed versus resistant/intolerant CML) and the patient's individual clinical characteristics. Precise adherence to the dosing schedule and fasting requirements is critical for both efficacy and safety. The treating oncologist or hematologist will determine the most appropriate dose and make adjustments based on treatment response and tolerability.
Adults
Newly Diagnosed Chronic-Phase Ph+ CML
Dose: 300 mg orally twice daily (total daily dose: 600 mg)
Schedule: Approximately 12 hours apart (e.g., morning and evening)
Fasting: No food for 2 hours before and 1 hour after each dose
Duration: Continue as long as the patient derives clinical benefit or until unacceptable toxicity
Resistant/Intolerant Chronic-Phase or Accelerated-Phase Ph+ CML
Dose: 400 mg orally twice daily (total daily dose: 800 mg)
Schedule: Approximately 12 hours apart
Fasting: No food for 2 hours before and 1 hour after each dose
Duration: Continue as long as the patient derives clinical benefit
The capsules must be swallowed whole with water. For patients who are unable to swallow capsules, the contents may be dispersed in approximately one teaspoon of apple sauce (apple puree) and taken immediately. No other food or beverages (other than water and apple sauce for dispersion) should be used, as these may alter drug absorption unpredictably.
Children and Adolescents
Pediatric Patients (Age 1 Year and Older)
Dose: Based on body surface area (BSA), approximately 230 mg/m² twice daily for newly diagnosed CML and 230 mg/m² twice daily for resistant/intolerant CML, rounded to the nearest 50 mg capsule. Maximum single dose should not exceed 400 mg.
Schedule: Approximately 12 hours apart on an empty stomach
Note: Pediatric dosing should be determined and supervised by a specialist in pediatric oncology. Growth and development should be monitored regularly.
Elderly Patients
No specific dose adjustments are required solely based on age. However, elderly patients are more likely to have comorbidities (particularly cardiovascular disease), impaired hepatic or renal function, and concurrent medications that may affect nilotinib pharmacokinetics or increase the risk of adverse effects. Elderly patients should therefore be monitored more closely, with particular attention to cardiac function (ECG monitoring), blood counts, and liver function. Dose modifications should be made based on individual tolerability and the presence of organ impairment rather than age alone.
Missed Dose
If a dose of nilotinib is missed, the patient should not take a double dose to make up for it. Instead, the patient should take the next scheduled dose at the regular time. Taking a double dose increases the risk of QT prolongation and other dose-dependent adverse effects. Patients should be counseled about the importance of adherence and provided with strategies to help remember their doses, such as setting alarms or using pill organizers. If doses are frequently missed, the patient should discuss this with their healthcare provider, as suboptimal adherence can lead to treatment failure and disease progression.
Overdose
In the event of an overdose of nilotinib, there is no specific antidote. Treatment is supportive and symptomatic. Given the risk of QT prolongation, immediate cardiac monitoring with continuous ECG is essential. Electrolytes (potassium, magnesium, calcium) should be checked and corrected urgently. Gastric lavage and/or activated charcoal may be considered if the overdose is recent. Nilotinib is highly protein-bound (approximately 98%) and therefore hemodialysis is unlikely to be effective in removing the drug from the circulation. The patient should be monitored in a hospital setting for cardiac arrhythmias, hepatic dysfunction, and myelosuppression for an appropriate period based on the amount ingested.
| Patient Group | Indication | Dose | Frequency |
|---|---|---|---|
| Adults — newly diagnosed | Chronic-phase Ph+ CML | 300 mg | Twice daily |
| Adults — resistant/intolerant | Chronic/accelerated-phase Ph+ CML | 400 mg | Twice daily |
| Pediatric (≥1 year) | Ph+ CML (newly diagnosed or resistant) | 230 mg/m² (max 400 mg) | Twice daily |
| Elderly | As per adult indication | No age-specific adjustment | Monitor closely |
| Hepatic impairment (mild/moderate) | Any indication | Reduced starting dose; close monitoring | Twice daily |
What Are the Side Effects of Nilotinib Zentiva?
Like all medications, nilotinib can cause side effects, although not everyone will experience them. The side effect profile of nilotinib has been well characterized through large clinical trials involving thousands of patients and extensive post-marketing surveillance. Understanding the frequency and nature of these side effects is important for patients and their caregivers, as many can be managed effectively with appropriate monitoring and intervention.
The side effects are classified below according to their frequency, using the standard medical classification system. This classification helps patients and healthcare providers understand how likely each side effect is to occur:
Very Common
- Rash (skin eruption)
- Headache
- Nausea
- Fatigue and asthenia
- Pruritus (itching)
- Alopecia (hair thinning)
- Myalgia (muscle pain)
- Upper respiratory tract infection (nasopharyngitis)
- Neutropenia (low neutrophil count) — laboratory finding
- Thrombocytopenia (low platelet count) — laboratory finding
- Elevated bilirubin — laboratory finding
- Elevated lipase — laboratory finding
Common
- Constipation, diarrhea, vomiting, abdominal pain
- Arthralgia (joint pain)
- Bone pain, pain in extremities
- Peripheral edema (swelling of hands/feet)
- Dizziness
- Insomnia
- Dry skin, erythema (redness), eczema
- QT prolongation on ECG
- Hyperbilirubinemia (jaundice)
- Hyperglycemia (elevated blood sugar)
- Hypercholesterolemia, hyperlipidemia
- Decreased appetite
- Anemia — laboratory finding
- Elevated ALT, AST (liver enzymes)
Uncommon
- Pancreatitis (inflammation of the pancreas)
- Peripheral arterial occlusive disease (PAOD)
- Ischemic heart disease, angina pectoris
- Cerebrovascular events (stroke, TIA)
- Pericardial effusion
- Hepatotoxicity, hepatic failure
- Pleural effusion
- Diabetes mellitus
- Tumor lysis syndrome
- Gastrointestinal hemorrhage
Rare
- Sudden cardiac death
- Torsades de pointes (ventricular arrhythmia)
- Hepatic failure requiring transplantation
- Anaphylactic reaction
- Stevens-Johnson syndrome / toxic epidermal necrolysis
- Papilledema (swelling of the optic disc)
Frequency Not Known
- Hepatitis B reactivation
- Hyperammonemia
- Oral mucosal blistering
It is important to note that many of the laboratory abnormalities listed above (such as neutropenia, thrombocytopenia, and elevated liver enzymes) may not cause noticeable symptoms but are detected through routine blood tests. This underscores the importance of regular monitoring appointments. Patients should report any new or worsening symptoms to their healthcare provider promptly, particularly chest pain, palpitations, unusual bleeding or bruising, severe abdominal pain, yellowing of the skin or eyes, unexplained fever, or leg pain or coldness in the extremities (which could indicate peripheral arterial disease).
Contact your doctor or go to the nearest emergency department immediately if you experience: chest pain or irregular heartbeat; sudden numbness or weakness on one side of the body; severe abdominal pain with nausea and vomiting (possible pancreatitis); yellowing of the skin or whites of the eyes (possible liver damage); high fever with signs of infection; or unusual bleeding that does not stop. These symptoms may indicate serious adverse effects that require urgent medical evaluation.
How Should You Store Nilotinib Zentiva?
Proper storage of nilotinib is essential to maintain the medication's stability, potency, and safety. Nilotinib Zentiva hard capsules should be stored at a temperature not exceeding 30°C (86°F). The medication should be kept in its original packaging (blister pack or bottle) to protect the capsules from moisture, which can degrade the active ingredient and affect the medication's effectiveness.
The capsules should be kept in a secure location that is out of the reach and sight of children. This is particularly important because nilotinib is a cytotoxic medication, and accidental ingestion by a child could have serious consequences. Patients should not transfer the capsules to other containers (such as daily pill organizers) for extended periods, as this removes the protective packaging. If a pill organizer is used, it should be filled for only a few days at a time and stored in a cool, dry environment.
Do not use nilotinib after the expiry date printed on the outer carton and blister pack or bottle label. The expiry date refers to the last day of the indicated month. Expired medication may not only be less effective but could also produce potentially harmful degradation products. Any unused or expired medication should be returned to a pharmacy for proper disposal. Do not dispose of nilotinib in household waste or wastewater, as the cytotoxic nature of the drug means it can contaminate the environment and pose risks to others.
What Does Nilotinib Zentiva Contain?
Understanding the complete composition of a medication is important for patients who may have allergies or intolerances to specific ingredients. Nilotinib Zentiva hard capsules contain the following components:
Active substance: Each capsule contains 50 mg of nilotinib (as nilotinib hydrochloride monohydrate). Nilotinib hydrochloride monohydrate is a white to slightly yellowish powder that is practically insoluble in water at neutral pH but shows pH-dependent solubility, being more soluble in acidic conditions. This pH-dependent solubility is one reason why proton pump inhibitors can reduce nilotinib absorption.
Excipients (inactive ingredients): The capsule formulation contains various inactive ingredients that serve specific pharmaceutical functions. These typically include:
- Lactose monohydrate — filler and diluent. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medication without consulting their doctor.
- Crospovidone — disintegrant to help the capsule contents break apart in the gastrointestinal tract
- Poloxamer 188 — wetting agent to improve drug dissolution
- Colloidal silicon dioxide — glidant to improve powder flow during manufacturing
- Magnesium stearate — lubricant to prevent the powder from sticking to manufacturing equipment
Capsule shell: The hard capsule shell is composed of gelatin and may contain colorants such as titanium dioxide (E171), iron oxide yellow (E172), and iron oxide red (E172). The specific appearance of the capsule (color and markings) may vary depending on the strength and manufacturer.
Patients should always check the patient information leaflet supplied with their specific product for the most accurate and up-to-date list of ingredients, as formulations may vary between different generic manufacturers. If you have any known allergies to any of the listed ingredients, inform your healthcare provider before starting treatment.
Frequently Asked Questions About Nilotinib Zentiva
Nilotinib Zentiva is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a type of blood cancer. It is a second-generation BCR-ABL tyrosine kinase inhibitor that works by blocking the abnormal protein (BCR-ABL) responsible for the uncontrolled growth of leukemic white blood cells. It can be used as first-line treatment in newly diagnosed adults and children, or as second-line treatment in patients who did not respond to or could not tolerate previous therapy with imatinib.
Food dramatically increases the absorption of nilotinib — by up to 82%. This leads to significantly higher drug levels in the blood, which increases the risk of dangerous QT prolongation (a heart rhythm abnormality that can cause life-threatening arrhythmias). To ensure safe and consistent drug levels, you must fast for at least 2 hours before and 1 hour after each dose. Only water is allowed during these fasting periods.
Nilotinib Zentiva is a generic version of nilotinib, originally marketed as Tasigna by Novartis. Both contain the same active ingredient (nilotinib) and have the same mechanism of action. Generic medications must meet strict bioequivalence standards set by regulatory authorities like the EMA and FDA, meaning they are required to deliver the same amount of active drug into the bloodstream as the branded product. Your doctor and pharmacist can advise you on the interchangeability of generic and branded formulations.
Treatment-free remission (TFR) is a possibility for some CML patients, but it must only be attempted under very specific conditions and close specialist supervision. To be eligible, patients typically need to have achieved and maintained a deep molecular response (MR4.5 or better, meaning BCR-ABL transcript levels of 0.0032% or less on the International Scale) for at least 2 years. After discontinuation, frequent molecular monitoring is required, as approximately half of patients may experience molecular relapse and need to restart treatment. Never stop taking nilotinib on your own without your doctor's guidance.
Regular monitoring is essential during nilotinib treatment and includes: ECG (electrocardiogram) at baseline, 7 days after starting, and periodically during treatment; complete blood counts every 2 weeks for the first 2 months, then monthly; liver function tests monthly; serum lipase periodically; electrolytes (potassium, magnesium, calcium) before starting and periodically thereafter; blood glucose and lipid profiles; and molecular monitoring of BCR-ABL transcript levels to assess treatment response. Additional monitoring may be required based on individual risk factors.
Yes, nilotinib is approved for use in pediatric patients aged 1 year and older with Ph+ CML. The dose for children is calculated based on body surface area (approximately 230 mg/m² twice daily, rounded to the nearest 50 mg capsule, with a maximum single dose of 400 mg). Treatment in children must be supervised by a specialist in pediatric oncology, with regular monitoring of growth, development, and the same safety parameters as for adults. For children who cannot swallow capsules, the contents may be dispersed in apple sauce.
References
- European Medicines Agency (EMA). Nilotinib – Summary of Product Characteristics. Available at: www.ema.europa.eu. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Tasigna (nilotinib) – Prescribing Information. Available at: www.fda.gov. Accessed January 2026.
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259. doi:10.1056/NEJMoa0912614
- Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-1054. doi:10.1038/leu.2016.5
- Kantarjian H, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-3546. doi:10.1182/blood-2007-03-080689
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 1.2026. Available at: www.nccn.org.
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984. doi:10.1038/s41375-020-0776-2
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List. 2023. Available at: www.who.int.
- Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv41-iv51. doi:10.1093/annonc/mdx219
- Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298-305. doi:10.1200/JCO.2016.68.2914
Editorial Team
This article has been written and reviewed by medical professionals to ensure accuracy and clinical relevance. All content follows international evidence-based guidelines.
Medical Writer
iMedic Medical Editorial Team — Specialists in Oncology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board — Independent panel following ESMO, NCCN, ELN, EMA, and FDA guidelines
Evidence Level
Level 1A — Based on systematic reviews and randomized controlled trials (ENESTnd, ENEST1st)
Last Reviewed
January 24, 2026 — Next review scheduled within 12 months